An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.

Hims is a telehealth company offering discreet virtual consultations and prescription delivery for men's health concerns. Hims' hair loss program uses FDA-approved treatments like finasteride and ...

The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc‘s HIMS peptide ...

Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 ...

S&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across telehealth and online health services, peers were mixed: Teladoc Health ...

Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth ...

The telehealth company reported first-quarter 2026 revenue of $608.1 million, up 4% year over year, while subscribers continued growing across its weight-loss, sexual health, dermatology, and primary ...

Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating. The catalyst: the FDA took a ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical ...